Genetically modified human CD4+T cells can be evaluatedin vivowithout lethal graft-versus-host disease
- 18 July 2016
- journal article
- Published by Wiley in Immunology
- Vol. 148 (4) , 339-351
Abstract
Adoptive cell immunotherapy for human diseases, including the use of T cells modified to express an anti-tumour T-cell receptor (TCR) or chimeric antigen receptor, is showing promise as an effective treatment modality. Further advances would be accelerated by the availability of a mouse model that would permit human T-cell engineering protocols and proposed genetic modifications to be evaluated in vivo. NOD-scid IL2rγ(null) (NSG) mice accept the engraftment of mature human T cells; however, long-term evaluation of transferred cells has been hampered by the xenogeneic graft-versus-host disease (GVHD) that occurs soon after cell transfer. We modified human primary CD4(+) T cells by lentiviral transduction to express a human TCR that recognizes a pancreatic beta cell-derived peptide in the context of HLA-DR4. The TCR-transduced cells were transferred to NSG mice engineered to express HLA-DR4 and to be deficient for murine class II MHC molecules. CD4(+) T-cell-depleted peripheral blood mononuclear cells were also transferred to facilitate engraftment. The transduced cells exhibited long-term survival (up to 3 months post-transfer) and lethal GVHD was not observed. This favourable outcome was dependent upon the pre-transfer T-cell transduction and culture conditions, which influenced both the kinetics of engraftment and the development of GVHD. This approach should now permit human T-cell transduction protocols and genetic modifications to be evaluated in vivo, and it should also facilitate the development of human disease models that incorporate human T cells.Keywords
Funding Information
- National Institutes of Health (R01 DK094327, R01 DK064315, R03 AI119225, R21 AI112321, UC4 DK104218, P60 DK020541)
- Einstein-Mount Sinai Diabetes Research Center (P30 CA013330)
- Einstein Flow Cytometry Facility (P30 CA034196)
- The Jackson Laboratory
- The Helmsley Charitable Trust (2015PG-T1D057)
This publication has 42 references indexed in Scilit:
- Humanized Mouse Models for Transplant ImmunologyAmerican Journal of Transplantation, 2015
- Humanized mice for immune system investigation: progress, promise and challengesNature Reviews Immunology, 2012
- Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnullhumanized miceProceedings of the National Academy of Sciences, 2010
- Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic miceJournal of Autoimmunity, 2008
- Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8 + T cells in NOD miceProceedings of the National Academy of Sciences, 2008
- Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cellsClinical Immunology, 2006
- Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65)Proceedings of the National Academy of Sciences, 2001
- Retroviral vector-mediated gene transfer into keratocytes: in vitro effects of polybrene and protamine sulfateGraefe's Archive for Clinical and Experimental Ophthalmology, 1998
- Human T-cell receptor variable gene segment familiesImmunogenetics, 1995
- Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif.1994